儿科风湿病学中的生物类似药:创新,挑战和机遇
Ali Öksel1, Hafize Emine Sönmez2, Nihal Şahin2
1Pediatrics, Medical Park Hospital, Kocaeli, Turkey.
Expert opinion on biological therapy
|January 11, 2025
概括
生物类药物为儿童类风湿病提供成本效益高的生物修饰性抗风湿药物 (bDMARDs). 本综述涵盖了它们的发展,安全性,有效性和采用挑战,强调为明智的临床决策提供教育.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 生物仿制药是生物药物,它们非常接近已批准的生物疾病修饰性抗风湿药物 (bDMARDs).
- 它们在2013年与infliximab一起在儿科风湿病学中引入,扩大了儿童风湿病的治疗选择.
- 随后的乙坦塞普特,利图西马布和阿达利穆马布的生物仿制药现在已经可用.
研究的目的:
- 探索生物仿制药在儿科风湿病学中的作用,重点关注青少年异常性关节炎.
- 审查儿童类风湿性疾病中生物类似药的开发,安全性,疗效和临床采用方面的挑战.
- 突出患者和医疗保健提供者关于生物类似药的使用教育的重要性.
主要方法:
- 目前科学出版物的文献综述.
- 对儿科风湿病学中生物类似药的安全性,疗效和经济影响数据的分析.
- 探索临床采用的挑战和有效实施的策略.
主要成果:
- 生物类似药在儿科风湿病学中提供安全有效的治疗替代方案.
- 经济效益和扩大治疗机会是关键优势.
- 教育,沟通和期望管理对于成功的整合至关重要.
结论:
- 生物类似药在儿科风湿病学中是有价值的治疗选择,提供成本效益和扩大获取.
- 通过教育和清晰的沟通来应对挑战,对于最佳的患者护理和治疗连续性至关重要.
- 进一步的研究和持续的监测对于支持适当使用生物类似药物至关重要.
相关概念视频
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.